Programme 2021

Digital Programme

5th AMR Conference
Summer Edition | AMR Briefing Sessions

Each day offered an AMR briefing session on a dedicated topic, including live speakers, high-level panel discussions, and interactive exchange with the audience:

Status quo & COVID-19 Impact | Financing & Investing | Policy & Incentives

Overall theme of the day:
Status quo & COVID-19 Impact – What has changed after one year of COVID?

02:00 p.m. – 02:45 p.m. CEST

Opening | Keynotes 



  • David Barros-Aguirre, VP, Head of GSK Global Health Pharma R&D Unit, Tres Cantos, Spain
  • Justin Yang, Director, Catalyst Office, BARDA, Division of Research Innovation and Ventures (DRIVe) & Founder of BARDA Ventures, US
  • Janet Hemingway, Founding Director of the Infection Innovation Consortium (iiCON), UK
02:45 p.m. – 03:30 p.m. CEST

Panel discussion – What has changed in the fight against AMR after one year of COVID?


  • all previous opening speakers
  • Marco Cavaleri, Head of Biological Health Threats and Vaccines Strategy, EMA
03:30 p.m. – 04:15 p.m. CEST

Spotlight on: AMR innovation during the pandemic – challenges and best-practices


  • Jessica Boname, Head of Antimicrobial Resistance, Medical Research Council, UK & Member of the JPI AMR Management Board


  • Christoph Dehio, Professor of Molecular Microbiology at University of Basel, Switzerland & Director of NCCR AntiResist
  • Jürgen Popp, Chair for Physical Chemistry, Friedrich-Schiller University Jena & Scientific director of Leibniz Institute of Photonic Technology, Jena, Germany
  • Philippe Villain-Guillot, CEO & Co-founder, Nosopharm, France

Overall theme of the day:
Financing & Investing – What’s new with funds, incubators and accelerators?

02:00 p.m. – 03:00 p.m. CEST

Panel discussion:
Infectious diseases in the spotlight – How investors evaluate AMR innovation



 03:00 p.m. – 04:15 p.m. CEST

Focus on incubators and public-private accelerators in US and Europe – How they drive the AMR innovation pipeline



  • Anders Karlén, Professor in Computer-Aided Drug Design, Uppsala University, Sweden & Coordination team of the IMI AMR Accelerator 
  • Erin Duffy, Chief of Research & Development, CARB-X, US
  • Douglas Häggström, Community Manager INCATE,
    Innovation Office, University of Basel, Switzerland
  • Igor Orshanskiy, Director Business Development & Licensing, External Innovations & Alliances, AiCuris Anti-infective Cures, Germany 

Overall theme of the day:
Policy & Incentives – What can we learn from best practices to go ahead?

02:00 p.m. – 03:15 p.m. CEST

Keynotes | Panel

What can we expect and learn from the US and UK pull incentive initiatives?



  • Enrico Baraldi, Professor of Industrial Engineering & Manager of PLATINEA, University of Uppsala, Sweden & Caline Mattar, Assistant Professor of Medicine, Washington University in St Louis, US
  • Colm Leonard, Consultant Clinical Adviser, NICE, UK & David Glover, Deputy Head of the Medicines Analysis Team, NHS England, UK
  • Kevin Outterson, Professor of Law & Executive Director, CARB-X, US
03:15 p.m. – 04:15 p.m. CEST

Outlook: How to further drive pull incentives on the policy agenda


  • Peter Beyer, Unit Head, Impact Initiatives and Research Coordination, AMR Division, WHO


BEAM Alliance programme committee

Marc Gitzinger

CEO, BioVersys AG & President, BEAM Alliance

Marc Lemonnier

Founding CEO, Antabio SAS

Deborah O’Neil

CEO, NovaBiotics Ltd & Board Member, BEAM Alliance